Neonatal Retinopathy Screening And Laser Treatment
Retinopathy of prematurity (ROP) is a disorder of abnormal retinal blood vessel development in premature infants. It can resolve without treatment, yet rapidly progressing disease may cause retinal detachment and permanent visual impairment. Careful screening allows clinicians to identify infants at risk before retinal damage becomes irreversible.
The condition is closely associated with immature retinal vascularization, low gestational age, low birth weight, respiratory illness, and fluctuating oxygen exposure. Modern neonatal care has improved survival among extremely premature babies, making organized eye surveillance an essential part of perinatal and neonatal medicine.
The FAOPS 2020 website preserves information about a scientific meeting that was planned to bring together specialists in these fields in Tokyo. Its perinatal medicine program reflects the broad clinical and research setting in which neonatal ophthalmology, intensive care, and developmental outcomes are considered together.
Why early retinal screening matters
Before birth, retinal blood vessels develop outward from the optic nerve toward the edges of the retina. In a very premature infant, this process is incomplete. After birth, changes in oxygenation and growth signals can cause abnormal vessels to grow, leak, or form traction on the retina.
ROP may be mild and self-limited, but its appearance can change quickly. The most dangerous findings include disease in the posterior retina, extensive abnormal vessels, and “plus disease,” a term describing venous dilation and arterial tortuosity in the posterior pole. These signs indicate active vascular stress and a higher risk of progression.
Screening is therefore a preventive examination rather than a response to visible symptoms. Babies with significant ROP usually do not appear uncomfortable, and parents may not notice a problem until advanced disease has developed. A timely retinal examination is the only dependable way to detect the early stages.
Which infants need examination
Screening criteria differ slightly among national and regional guidelines because neonatal populations and available resources vary. Common eligibility factors include birth at or below approximately 30–31 weeks’ gestation or a birth weight below 1500 grams. Larger or more mature infants may also require screening when their clinical course has included prolonged oxygen therapy, severe respiratory disease, sepsis, transfusions, poor postnatal growth, or other instability.
Gestational age should be based on the best obstetric and neonatal assessment available. When gestational age is uncertain, clinicians generally use the risk profile and clinical course to avoid missing an infant who may have incomplete retinal vascularization. Decisions should follow the protocol used by the local neonatal and ophthalmology services.
The first examination is scheduled according to both postmenstrual age and chronological age. Very immature infants are often examined at a specific postmenstrual age, while more mature premature infants are commonly examined several weeks after birth. The exact timing depends on gestational age, birth weight, and guideline requirements; an early or late appointment should never be arranged casually.
What the eye examination evaluates
A trained ophthalmologist examines the peripheral retina after pharmacologic pupil dilation. Indirect ophthalmoscopy remains a standard method, while wide-field digital retinal imaging can support documentation, remote review, and quality assurance. Imaging does not remove the need for a clinician capable of recognizing subtle vascular abnormalities.
The examination records the retinal zone, disease stage, and presence or absence of plus disease. Zone I is the central area around the optic nerve, zone II extends farther toward the periphery, and zone III represents the remaining temporal crescent. Disease located closer to the optic nerve generally carries greater risk than disease in the far peripheral retina.
Stages describe the appearance of the junction between vascularized and avascular retina. Stage 1 is a demarcation line, stage 2 is an elevated ridge, and stage 3 includes extraretinal fibrovascular proliferation. Stage 4 represents partial retinal detachment, while stage 5 involves total detachment. Aggressive posterior ROP can progress rapidly and may not fit neatly into the usual sequence.
Follow-up intervals depend on the findings. An immature vascular pattern may require repeated observation every one or two weeks, while suspicious or rapidly changing disease may require assessment within days. Screening must continue until the retina is adequately vascularized, ROP has clearly regressed, or treatment and subsequent examinations establish a safe endpoint.
How treatment decisions are made
Treatment is based on the risk of vision-threatening progression rather than on prematurity alone. The classic term “threshold disease” has largely been replaced by treatment categories derived from clinical trial evidence. Type 1 ROP generally requires prompt treatment, whereas type 2 disease can often be monitored closely.
Typical type 1 patterns include zone I disease with plus disease, zone I stage 3 without plus disease, and zone II stage 2 or stage 3 with plus disease. Aggressive posterior ROP is treated urgently because deterioration may occur over a short period. The treating team also considers examination quality, rate of progression, systemic stability, and the ability to complete follow-up.
Observation is appropriate only when the infant can receive reliable, timely reassessment. A missed appointment can allow active ROP to worsen unnoticed. Neonatal units should establish clear responsibility for scheduling, transport, communication with parents, and escalation when an examination is delayed.
| Treatment approach | Main role | Important advantages | Key limitations |
|---|---|---|---|
| Careful observation | Low-risk or type 2 ROP | Avoids procedural injury and anesthesia exposure | Requires dependable repeat examinations |
| Laser photocoagulation | Established treatment for type 1 ROP | Durable treatment of the avascular peripheral retina | Can reduce peripheral vision and requires access to the retina |
| Anti-VEGF injection | Selected posterior, aggressive, or extensive disease | Useful when laser access is difficult or the retina is poorly visualized | Recurrence can occur months later; systemic and developmental safety remain important considerations |
| Combined or rescue treatment | Persistent, recurrent, or complex ROP | Addresses disease that is not controlled by one method | Demands specialist expertise and prolonged surveillance |
How laser therapy works
Laser photocoagulation treats the avascular peripheral retina rather than the abnormal vessels directly. By applying controlled laser burns to areas that have not developed normal blood vessels, treatment reduces the retinal drive for abnormal vascular growth. The aim is to stop progression before traction causes retinal detachment.
The procedure is usually performed under conditions that provide adequate analgesia, monitoring, and immobilization. Depending on the infant’s condition and hospital resources, this may involve topical medication, sedation, or general anesthesia. The ophthalmology and neonatal teams must balance procedural comfort, respiratory risk, cardiovascular stability, and the need for a complete treatment.
Laser treatment is highly effective when performed at the appropriate stage, but it is not without consequences. It can destroy some peripheral retina, potentially affecting peripheral visual field and night vision. Other risks include inflammation, pressure changes, bleeding, incomplete treatment, and recurrent disease. A single session may not be sufficient if the retina is difficult to visualize or disease remains active.
After treatment, the infant needs close review to confirm regression and detect complications. Persistent plus disease, new fibrovascular proliferation, or an incomplete laser pattern may require additional treatment. Families should receive a clear written plan because follow-up remains essential even when the eyes initially appear improved.
Where anti-VEGF treatment fits
Intravitreal anti-vascular endothelial growth factor medications inhibit a signal that drives abnormal retinal vessel growth. They may be considered for zone I disease, aggressive posterior ROP, or cases in which media opacity, poor access, or the extent of avascular retina makes laser unsuitable. Some infants receive anti-VEGF therapy as an initial treatment, while others receive it after incomplete laser response.
The apparent short-term benefit can be substantial, particularly in posterior disease. However, anti-VEGF treatment does not immediately complete retinal vascular development. Reactivation may occur many weeks or months later, sometimes after the infant has left the neonatal service. Long-term follow-up until vascularization is complete is therefore critical.
Systemic exposure and effects on developing organs remain areas of ongoing research. Clinicians must weigh the severity and location of ROP, the infant’s overall condition, medication selection, informed parental consent, and the capacity for prolonged surveillance. Laser and anti-VEGF therapy are not interchangeable in every clinical situation.
Supporting families and long-term vision
Parents may feel overwhelmed by the number of neonatal appointments and unfamiliar ophthalmic terms. Explaining the purpose of screening, the meaning of zone and stage, and the reason for repeated examinations can improve attendance. Families should know that a baby may need follow-up even when the first examination shows only immature vessels.
Visual development continues after ROP has resolved. Premature infants have increased risks of refractive error, strabismus, amblyopia, cerebral visual impairment, and other developmental concerns. Treatment of acute ROP protects the retina, but it does not eliminate the need for later pediatric eye care and developmental assessment.
Communication between neonatologists, ophthalmologists, nurses, primary care clinicians, and families is especially important when infants move between hospitals. Digital imaging and telemedicine can help connect smaller neonatal units with specialists, although remote systems require validated equipment, trained image acquisition, secure data handling, and a dependable pathway for urgent in-person examination. Discussions about virtual scientific meetings also illustrate how digital communication can support professional collaboration when travel or access is limited.
Practical priorities for neonatal teams
A reliable ROP program combines evidence-based eligibility rules with disciplined follow-up. Each unit should adapt its process to local guidelines, referral pathways, staffing, and the clinical characteristics of its premature infant population.
Useful priorities include:
- Record gestational age, birth weight, oxygen exposure, major illnesses, and the planned first examination before hospital discharge.
- Use a written schedule that states the examination date, responsible clinician, findings, and next follow-up interval.
- Escalate urgent findings such as plus disease, aggressive posterior disease, or rapid progression without waiting for a routine appointment.
- Explain treatment options, expected follow-up, and missed-visit risks to parents in clear, nontechnical language.
- Continue ophthalmic surveillance after treatment until regression, adequate vascularization, or a specialist-defined endpoint is documented.
Early recognition gives treatment the best chance of preserving useful vision. Neonatal units, ophthalmology services, and families can strengthen that protection by treating every scheduled examination as time-sensitive. Clinical teams should apply current local guidelines, maintain specialist referral arrangements, and ensure that no premature infant is lost between screening, treatment, and long-term follow-up.
